CN105579581A - 具有优化的a凸出物的重组载体 - Google Patents

具有优化的a凸出物的重组载体 Download PDF

Info

Publication number
CN105579581A
CN105579581A CN201480053358.9A CN201480053358A CN105579581A CN 105579581 A CN105579581 A CN 105579581A CN 201480053358 A CN201480053358 A CN 201480053358A CN 105579581 A CN105579581 A CN 105579581A
Authority
CN
China
Prior art keywords
sequence
restructuring
replication competent
retrovirus
competent type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480053358.9A
Other languages
English (en)
Chinese (zh)
Inventor
A·H·林
H·E·格鲁伯
C·伊巴涅斯
D·J·约利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forte Biosciences Inc
Original Assignee
Tocagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tocagen Inc filed Critical Tocagen Inc
Publication of CN105579581A publication Critical patent/CN105579581A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201480053358.9A 2013-08-05 2014-08-05 具有优化的a凸出物的重组载体 Pending CN105579581A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862433P 2013-08-05 2013-08-05
US61/862,433 2013-08-05
PCT/US2014/049831 WO2015021077A1 (en) 2013-08-05 2014-08-05 Recombinant vector with optimized a-bulge

Publications (1)

Publication Number Publication Date
CN105579581A true CN105579581A (zh) 2016-05-11

Family

ID=52461883

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480053358.9A Pending CN105579581A (zh) 2013-08-05 2014-08-05 具有优化的a凸出物的重组载体

Country Status (6)

Country Link
EP (1) EP3030659A4 (https=)
JP (1) JP2016526920A (https=)
CN (1) CN105579581A (https=)
AU (1) AU2014306093A1 (https=)
CA (1) CA2920049A1 (https=)
WO (1) WO2015021077A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
KR20220061977A (ko) 2019-08-12 2022-05-13 퓨리노미아 바이오테크, 아이엔씨. Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물
US20220395476A1 (en) * 2019-09-30 2022-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Drug for treating artery-related diseases, and use thereof
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CN115968300A (zh) * 2020-05-11 2023-04-14 艾宾妥斯生物公司 用于体内转导的载体和方法
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022165001A1 (en) 2021-01-29 2022-08-04 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
TW202332694A (zh) 2021-10-07 2023-08-16 英商阿凡克塔生命科學公司 血清半衰期延長之ｐｄ－ｌ１結合多肽
JP2025515486A (ja) 2022-04-29 2025-05-15 ピュリノミア バイオテック， インコーポレイテッド 好酸球駆動性疾患及び障害を治療するための方法及び組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells
US20110217267A1 (en) * 2008-09-26 2011-09-08 Tocagen Inc. Gene therapy vectors and cytosine deaminases
CN102459616A (zh) * 2009-06-17 2012-05-16 托卡根公司 复制型逆转录病毒载体的生产细胞
US20130130986A1 (en) * 2010-03-29 2013-05-23 Tocagen Inc. Cancer treatment with recombinant vector

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260568A1 (en) * 2004-04-30 2005-11-24 Min Gao Hepatitis C virus assays

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US20110217267A1 (en) * 2008-09-26 2011-09-08 Tocagen Inc. Gene therapy vectors and cytosine deaminases
CN102227503A (zh) * 2008-09-26 2011-10-26 托卡根公司 重组载体
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells
CN102459616A (zh) * 2009-06-17 2012-05-16 托卡根公司 复制型逆转录病毒载体的生产细胞
US20130130986A1 (en) * 2010-03-29 2013-05-23 Tocagen Inc. Cancer treatment with recombinant vector

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANN KAMINSKI等: "The polypyrimidine tract binding protein (PTB) requirement for internal initiation of translation of cardiovirus RNAs is conditional rather than absolute", 《RNA》 *
MICHAEL A. HOFFMAN等: "Mutational Analysis of the J-K Stem-Loop Region of the Encephalomyocarditis Virus IRES", 《JOURNAL OF VIROLOGY》 *
YURY A. BOCHKOV等: "Translational efficiency of EMCV IRES in bicistronic vectors is dependent upon IRES sequence and gene location", 《BIOTECHNIQUES》 *

Also Published As

Publication number Publication date
CA2920049A1 (en) 2015-02-12
WO2015021077A1 (en) 2015-02-12
JP2016526920A (ja) 2016-09-08
AU2014306093A2 (en) 2016-04-21
EP3030659A1 (en) 2016-06-15
EP3030659A4 (en) 2017-01-11
AU2014306093A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
ES2709481T3 (es) Vectores recombinantes
US10407666B2 (en) Recombinant vectors
US11279949B2 (en) Recombinant vectors comprising 2A peptide
JP6609663B2 (ja) 複製可能レトロウイルスベクターの産生細胞
CN105579581A (zh) 具有优化的a凸出物的重组载体
JP6419706B2 (ja) ミニプロモーターカセットを含むレトロウイルスベクター
US20160222412A1 (en) Recombinant vector with stabilizing a-loop
EP3880829A1 (en) Recombinant vectors comprising genes for binding domains and secretable peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160511

WD01 Invention patent application deemed withdrawn after publication